

Serum BMP8B levels in women

with polycystic ovary syndrome: a case-control study

HUI-LING XUE[#]; WAN-JIAO HAO[#]; JIE SONG; YE LI; MAN LIU; JUN-XIU WEI; XIAO-PANG REN *

Department of Obstetrics and Gynecology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China

ABSTRACT

Objectives: Bone morphogenetic protein-8B (BMP8B) is an adipokine that is synthesized in many tissues and has been shown to be associated with the development of obesity and metabolic disorders in animals and humans. The aim of this study is to investigate the relationship between serum BMP8B levels and various metabolic parameters in women with PCOS.

Material and methods: This cross-sectional study included 80 women with PCOS and 40 age- and BMI-matched controls without PCOS. BMP8B, total cholesterol, triglyceride, fasting blood glucose (FBG), insulin, total testosterone (T), follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels were measured in all the participants. HOMA-IR was used to calculate the insulin resistance.

Results: Serum BMP8B levels were lower in women with PCOS than in healthy women (43.11 ± 13.09 [ng/mL] vs. 106.45 ± 52.32 [ng/mL], $p < 0.001$). HOMA-IR, LH/FSH, total-testosterone, total cholesterol, and triglyceride levels were significantly higher in women with PCOS than controls. Circulating BMP8B levels were positively correlated with HOMA-IR, BMI in PCOS group; was positively correlated with triglyceride in Control group.

Conclusion: The low concentration of circulating BMP8B in PCOS may be associated with insulin resistance, Lipid metabolism and BMI, but may be a new target for PCOS treatment.

Key words: polycystic ovary syndrome, BMP8B, brown adipose tissue, obesity, insulin resistance

INTRODUCTION

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive-aged women, with impacts across the lifespan from adolescence to post menopause. with a worldwide prevalence ranging from 6 to 21%, depending on the diagnostic criteria [1–5], is characterized by ovulatory dysfunction, polycystic ovaries and biochemical (elevated androgens) and/or clinical (hirsutism, acne) hyperandrogenism. It is associated with insulin resistance, glucose intolerance, metabolic syndrome, obesity, hyperlipidemia, hypertension, chronic low-grade inflammation and increased risk of developing type 2 diabetes mellitus (T2DM) [6–9]. but the etiology of PCOS is unknown, the pathogenesis is complex, the clinical heterogeneity is large, the diagnostic criteria are still controversial, and the diagnosis and treatment choice and management strategy are different.

Brown adipose tissue (BAT) is a specialized fat tissue that serves as the primary site for adaptive nonshivering thermogenesis to generate heat under cold stress in mammals. BAT

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

participates in primary metabolism and energy expenditure (EE), and it can be quickly stimulated by thermal or dietary stimulation [10]. A recent study showed that an increase in BAT mass and/or function could be an effective therapeutic target for the treatment of obesity and other related metabolic diseases in patients[11]. Brown adipokines are regulatory factors secreted by brown adipocytes that possess autocrine, paracrine, and endocrine activities and regulate BAT differentiation [12]. Some adipokines display hormonal functions that increase BAT activity, improve the metabolic profile of glucose and lipid homeostasis, and mediate the browning of WAT [13–15]. Bone morphogenetic protein-8B (BMP8B) is an adipokine produced by brown adipose tissue (BAT) contributing to thermoregulation and metabolic homeostasis in rodent models. [16]. Recent studies have shown that BMP8B plays an important role in energy metabolism and regulation of obesity. BMP8B can promote the increase of heat production, the acceleration of metabolism, and the reduction of body mass. It can also regulate lipid metabolism and has the effect of prosteatosis[17]. Yet, the role of BMP8B has not been fully understood in human homeostasis. Despite some studies on T2DM, metabolic syndrome and BMP8B, the relationship between BMP8B and PCOS has not been researched yet. For this reason, the aim of this study is to investigate the relationship between serum BMP8B levels and various metabolic parameters in patients with PCOS.

MATERIAL AND METHODS

This cross-sectional clinical trial study was conducted in Affiliated Hospital of Hebei University. The institutional ethical committee has approved the trial protocol. We enrolled in the study a total of 120 patients presenting to our reproductive medicine clinics. The study group composed of 80 women diagnosed with PCOS while the control group consisted of age and BMI matched 40 women that had regular menstrual cycles. Detailed history of all patients was taken. After a physical exam we recorded anthropometric data (age, weight, height). Height [cm] and weight [kg] were measured with the patient barefoot in light daily clothes. BMI was calculated using the formula: weight [kg]/square meter of height [m²]. Patients were subdivided into obese, overweight, and control based on BMI: a BMI ≥ 28 kg/m² was considered obese, a BMI < 24 kg/m² was considered control, the BMI between 24 and 28 kg/m² was overweight[18]. Blood pressure was measured in the sitting position ensuring a min. of 15 [min] rest prior to measurement. The average of three measurements taken was calculated. The PCOS diagnosis was confirmed with at least two criteria according to the 2003 Rotterdam consensus: oligo-ovulation or anovulation, presence of polycystic ovaries on transvaginal ultrasound and hyperandrogenism present as a laboratory finding and/or symptoms. The biochemical hyperandrogenism was defined as total testosterone levels above the range that is regarded as normal (normal range: 0.01–0.48 nmol/L) [19]. For the evaluation of the polycystic ovaries' (PCO) morphology, all women underwent transvaginal ultrasonography in the early follicular phase. The presence of PCO was diagnosed with the presence of 12 or more follicles with a diameter of 2–9 mm and/or increased ovarian volume (> 10 cm³) of each ovary. Menstrual periods were characterized by oligomenorrhea (absence of menstruation for 45 days or more) or by amenorrhea (no menstrual period for 3 months or more) in the PCOS group. The control group menstrual periods were regular and lasted 25–32 days. Additionally, the control group had neither hirsutism nor hyperandrogenism. All participants were non-smokers and did not have any medical treatment in the past. Pregnant or lactating women, hyperprolactinemia, Cushing's syndrome, congenital adrenal hyperplasia, other diseases of the adrenal gland, thyroid disorders, impaired glucose tolerance, type 1 or type

2 diabetes mellitus and the use of insulin sensitizers or oral anti-diabetics were all excluded from the study.

Laboratory studies

Antecubital venous blood samples were taken from each female in the early follicular phase of menstruation (2nd to 4th day). The samples were centrifuged and separated from the serum and stored at -80°C for analysis.

Total cholesterol, triglycerides, fasting blood glucose (FBG), serum insulin, total testosterone (T), follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and BMP8B levels were measured.

Serum total cholesterol, and triglyceride levels were determined using an automated analyzer (Abbott Architect C 16000, IL, USA) with its own kits (Abbott Diagnostics, Wiesbaden, Germany).. Serum insulin levels were measured by an automated analyzer (Abbott Architect I2000, IL, USA) using a chemiluminescent microparticle immunoassay (CMIA) with its own kit (Abbott Diagnostics, Wiesbaden, Germany). Serum FSH, LH, E2, and T levels were measured with CMIA (Beckman Coulter Inc., Brea, CA, USA). Serum BMP8B concentrations were assessed by enzyme immunoassay (HENGYUAN, Shanghai, China). The intra-assay CV was $< 10\%$ and the inter-assay CV was $< 12\%$. Using the formula stated for the homeostasis model assessment of insulin resistance (HOMA-IR) method, the insulin resistance was calculated according to the formula: $\text{HOMA-IR} = \text{fasting insulin [mU/mL]} \times \text{fasting glucose [mg/dL]} / 22.5$. Patients with PCOS were grouped according to HOMA-IR: patients in the PCOS-IR group had HOMA-IR of ≥ 2.69 and those in the PCOS-non-IR group had HOMA-IR of < 2.69 [20,21].

Statistical analysis

All statistical analysis was performed using the Statistical Package for the Social Sciences Software, version 18.0. The normality of the data was tested using the Kolmogorov-Smirnov test and all continuous variables had normal distribution ($p > 0.05$). Continuous variables were presented as mean $\pm$ standard deviation (SD). The demographic and laboratory characteristics of women with and without PCOS were compared using the two-tailed independent sample t-test. The relationship between BMP8B and other parameters was assessed by Pearson correlation analysis. To investigate the relationship between independent BMP8B levels in PCOS development, multiple linear regression analyzes were performed to adjust for equivalence and to determine the independent relationships of BMP8B levels with age, BMI, HOMA-IR, T, LH/FSH, E2, and triglyceride. All independent variables in the multiple linear regressions were tested for multicollinearity. If the variance inflation factor (VIF) exceeded 2.5, the variable was considered to be collinear. All reported confidence interval (CI) values are calculated at the 95% level. A two-sided p value of < 0.05 was considered statistically significant.

RESULTS

1. Clinical and laboratory characteristics of the study population. The comparative demographic and laboratory parameters of women with and without PCOS are presented in Table 1. The cases were matched in terms of age. The parameter was similar and no statically significant differences were recorded between the groups ($p > 0.05$). Serum BMP8B levels were lower in women with PCOS than in healthy women and the difference was statically significant $43.11 \pm 13.09 \text{ ng/mL}$ vs. $106.45 \pm 52.32 \text{ ng/mL}$, $p = 0.000$). Serum Triglyceride, LH, HOMA-IR, and T levels were all significantly higher in women with PCOS than in healthy women.

Table 1. Comparison of demographic and laboratory characteristics of patients

Variables	Controls n = 40	PCOS n = 80	t	p
Age (years)	27.02±4.09	25.46±5.00	1.708	0.090
BMI [kg/m ²]	21.53±2.83	28.18±5.18	7.560	0.000
HOMA-IR	2.08±0.53	5.00±3.14	5.814	0.000
LH / FSH	1.00±0.43	2.11±1.06	6.352	0.021
T	0.22±0.10	0.56±0.66	3.199	0.002
BMP8B	106.45±52.32	43.11±13.09	10.242	0.000
Estradiol [pg/mL]	39.00±13.66	38.12±16.57	0.288	0.774
total cholesterol [mmol/L]	4.27±0.61	4.64±0.84	0.289	0.015
triglyceride [mmol/L]	0.82±0.29	1.89±1.39	4.794	0.000

2. We divided PCOS patients into normal body weight group, overweight group and obesity group according to different BMI (normal weight group $17 < \text{BMI} \leq 24$, overweight group $24 < \text{BMI} \leq 28$, obesity group $\text{BMI} > 28$), conducted inter-group comparison of each index, and compared it with the normal control group at the same time, so as to clarify the relationship between BMP8B and each index. Our results showed that, Patients with normal weight PCOS had higher levels of HOMA-IR, LH/FSHT, T and triglyceride than the normal control group with statistical significance, while BMP8B was significantly lower than the normal control group with statistical significance. Compared with the normal control group, overweight patients with PCOS had higher BMI, HOMA-IR, LH/FSHT, T and triglyceride, while BMP8B was significantly lower than the normal control group, which was statistically significant. Compared with the normal control group, the BMI, Total cholesterol, HOMA-IR, LH/FSHT, T and triglyceride of the obese patients with PCOS were all higher than the normal control group, while the BMP8B was significantly lower than the normal control group, which was statistically significant. The BMI, HOMA-IR and triglyceride levels of normal weight patients with PCOS were lower than those of overweight and obese patients with PCOS, which was statistically significant, while BMP8B was significantly higher than that of overweight and obese patients with PCOS, which was statistically significant. In overweight and obese patients with PCOS, there was no difference in all data except BMI.

Table 2. PCOS was grouped according to BMI and the data were compared with each other

Variables	Controls n = 40	PCOS-normal weight n = 18	PCOS-overweight n = 20	PCOS-obese n = 42	P1	P2	P3	P4	P5	P6
Age (years)	27.02 ±4.09	25.38 ±5.32	25.35 ±4.88	25.54 ±5.04	0.206	0.167	0.151	0.981	0.913	0.885
BMI [kg/m ²]	21.53 ±2.83	21.26 ±2.62	26.10 ±1.02	32.15 ±3.02	0.727	0.000	0.000	0.000	0.000	0.000

HOMA-IR	2.08 ± 0.53	2.88 ± 1.25	5.69 ± 4.03	5.58 ± 2.87	0.001	0.000	0.000	0.008	0.000	0.903
LH / FSH	1.00 ± 0.43	2.09 ± 1.08	2.03 ± 1.23	2.16 ± 0.99	0.000	0.000	0.000	0.874	0.788	0.638
T[ng/mL]	0.22 ± 0.10	0.84 ± 1.35	0.49 ± 0.24	0.48 ± 0.17	0.006	0.000	0.000	0.270	0.980	0.863
BMP8B	106.45 ± 52.32	53.31 ± 19.00	36.99 ± 3.92	41.65 ± 10.37	0.000	0.000	0.000	0.001	0.003	0.057
Estradiol [pg/mL]	39.00 ± 13.66	38.11 ± 18.75	41.88 ± 19.02	36.34 ± 14.34	0.840	0.502	0.393	0.542	0.691	0.206
Total cholesterol [mmol/L]	4.27 ± 0.61	4.45 ± 0.79	4.56 ± 1.13	4.77 ± 0.61	0.358	0.211	0.001	0.742	0.124	0.368
triglyceride [mmol/L]	0.82 ± 0.29	1.16 ± 0.48	1.71 ± 0.78	2.30 ± 1.72	0.002	0.000	0.000	0.015	0.008	0.151

P1:Controls.vs.PCOS- normal weight ;P2:Controls.vs. PCOS- overweight;P3:Controls.vs. PCOS- obese; P4: PCOS-normal weightvs. PCOS- overweight;P5: PCOS-normal weight.vs. PCOS- obese; P6: PCOS- overweight.vs. PCOS- obese。

3. We divided PCOS patients into insulin resistance group and non-insulin resistance group according to differences in HOMA-IR, and conducted inter-group comparison of all indicators, and compared them with normal control group at the same time, so as to clarify the relationship between BMP8B and the indicators. Our results show that, BMI, LH/FSHT, T, total cholestero and triglyceride were significantly higher in the PCOS non-insulin resistant group than in the normal control group. BMP8B decreased significantly. Compared to PCOS insulin resistance group

There was no significant difference in other indexes except BMI and HOMA-IR. BMI, LH/FSHT, T, total cholestero and triglyceride were significantly higher in the PCOS insulin resistance group than in the normal control group. BMP8B decreased significantly.

Table 3.. PCOS was grouped according to HOMA-IR and the data were compared with each other

Variables	Controls n = 40	PCOS-non-IR n =19	PCOS-IR n = 61	P1	P2	P3
Age (years)	27.02±4.09	25.31±5.72	25.50±4.81	0.195	0.104	0.885
BMI [kg/m2]	21.53±2.83	24.48±5.6	29.34±4.48	0.010	0.000	0.000
HOMA-IR	2.08±0.53	2.21±0.48	5.87±3.11	0.396	0.000	0.000
LH / FSH	1.00±0.43	1.97±1.06	2.16±1.07	0.000	0.000	0.516
T	0.22±0.10	0.59±0.23	0.56±0.75	0.000	0.007	0.859
BMP8B	106.45±52.32	45.92±18.84	42.23±10.77	0.000	0.000	0.286
Estradiol [pg/mL]	39.00±13.66	39.27±21.58	37.76±14.85	0.953	0.675	0.732

total cholesterol [mmol/L]	4.27 ± 0.61	4.75 ± 0.82	4.61 ± 0.85	0.016	0.033	0.537
triglyceride [mmol/L]	0.82 ± 0.29	1.45 ± 0.67	2.03 ± 1.53	0.000	0.000	0.110

P1:control.vs.PCOS-NON-IR; P2:control.vs.PCOS-IR;P3 P3: PCOS-NON-IR. vs. PCOS-IR;

4. Correlation analysis

Pearson's correlation coefficients are presented in Table 4. Correlation was calculated between BMP8B and various other parameters in the two groups of women. The triglyceride levels were positively correlated with HOMA-IR, BMI and total cholesterol in the PCOS groups. Circulating BMP8B levels were negative correlation with BMI and HOMA-IR in the PCOS group. In the normal group, circulating BMP8B levels were significantly negatively correlated with triglycerides.

Table 4. Correlation coefficients between BMP8B levels and clinical parameters

	BMP8B			
	PCOS		Control	
	r	P	r	P
Age	-0.123	0.275	-0.025	0.877
BMI	-0.240	0.032	-0.204	0.207
HOMA-IR	-0.246	0.028	0.100	0.538
LH / FSH	0.061	0.592	-0.111	0.931
T	-0.138	0.224	-0.047	0.772
Estradiol	-0.024	0.832	-0.157	0.335
total cholesterol	0.102	0.369	0.113	0.487
triglyceride	-0.079	0.486	-0.436	0.005

DISCUSSION

The clinical features of PCOS, such as insulin resistance, obesity, dyslipidaemia and hyperandrogenism, can be classified as metabolic syndrome. Accordingly, 43% of adult women and nearly one-third of adolescent teenagers with PCOS have metabolic syndrome [22]. IR, obesity and hyperandrogenism are inseparable in the pathogenesis of PCOS. Insulin resistance (IR) is common in PCOS patients. IR has been reported in approximately 50–80% of women with different phenotypes of PCOS in different races [23,24,25]. Hyperinsulinaemia caused by IR exerts a gonadotropin effect on the ovaries and decreases the expression of sex hormone-binding protein (SHBG), leading to the onset of hyperandrogenism [26,27]. Androgens can induce the accumulation of adipose tissue, especially abdominal fat tissue, and cause IR in subcutaneous adipose tissue [28,29]. Obesity, especially abdominal obesity, is associated with a variety of clinical features of PCOS. For example, due to adipose tissue dysfunction, adipocytes secrete non-physiological levels of adipokines, including IL6, IL8, TNF-α, leptin, adiponectin, resistin, lipocalin 2, monocyte chemoattractant protein-1 (MCP1), retinol binding protein-4 (RBP4), and CXC-chemokine ligand 5 (CXCL5), which may be involved in IR [30,31,32,33]. Obesity results from the proliferation of fat cells, three distinct stages can be divided for the process of adipogenesis: (1) commitment of MSCs to the lineage of adipocytes; (2) clonal expansion involving DNA and cell replication; (3) terminal differentiation, which involves the activation of specific transcription factors such as the peroxisome proliferator-activated receptor gamma

(PPAR γ) and the CCAAT/enhancer-binding protein (C/EBP) family. Changes in any of these three stages can affect fat formation. It has been reported that the prevalence of dyslipidaemia in PCOS patients is 70%, and the levels of low-density lipoprotein cholesterol (LDL-c), very-low-density lipoprotein cholesterol (VLDL-c), triglycerides (Tgs), and free fatty acid are increased, while the levels of high-density lipoprotein cholesterol (HDL-c) are decreased [34,35]. Dyslipidaemia is regarded as an important metabolic phenotype, although it is not a diagnostic criterion.

BAT was first described in small mammals and infants as an adaptation to defend against the cold [36,37]. BAT is the major site of adaptive non-shivering thermogenesis, both during cold exposure and after meals in so called postprandial thermogenesis. The inverse relationship between the BAT activity and body fatness suggests that BAT, through increasing energy expenditure, is protective against body fat accumulation [38,39]. This has led to BAT being viewed as a promising therapeutic target for combating human obesity and related metabolic disorders [40,41]. In addition, BAT also has a certain secretory effect, as an endocrine organ, it can secrete regulatory molecules that may affect metabolism, called batokines. It can communicate signals between multiple tissues and organs and play a role in systemic metabolic regulation. The identification of these secretory factors acting on the whole body is expected to provide a theoretical basis and scientific basis for the treatment of obesity and related chronic metabolic diseases. It was found that adipokine production in brown adipocytes was more responsive to androgen therapy than in white adipocytes [42]. Bone morphogenetic protein 8B (BMP8B), a member of the transforming growth factor beta (TGF β)-BMP superfamily, has recently emerged as a new batokine, secreted by brown/beige adipocytes [43]. Current data point to BMP8B as a major molecule in whole body metabolism by modulating i) BAT thermogenesis and the browning of white adipose tissue (WAT), through its action on AMP-activated protein kinase (AMPK) in the ventromedial nucleus of the hypothalamus [43,44,45].

In our study, it was found that the serum BMP8b level of patients with PCOS was significantly lower than that of the normal control group, with statistical significance, which may be related to the high androgen in patients with PCOS. Studies have shown that testosterone can reduce UCP1 and mitochondrial biogenesis in BAT in rats, inhibit the transcription of PGC1 α , a key regulator of UCP1 expression and mitochondrial biogenesis, significantly damage mitochondrial function, reduce mitochondrial respiratory function, and inhibit BAT function [42,46,47]. In our further research, we found that; The serum BMP8b level of PCOS patients with insulin resistance is also significantly lower than that of PCOS patients with normal insulin secretion, which may be because the decreased mitochondrial respiratory activity is also implicated in part, by insulin resistance [48,49,50]. YAN et al. [51] found that after YTHDF1 gene was knocked out in male mice fed high fat, body weight increase, glucose intolerance and insulin resistance unrelated to feeding occurred, while mice with YTHDF1 overexpression showed significant remission of glucose intolerance and insulin resistance. The expression of BMP8B protein in YTHDF1 knockout mice was significantly reduced. The mechanism may be that YTHDF1 gene knockout reduces the 3'-terminal non-coding sequence 1 luciferase activity of BMP8B and regulates the translation of BMP8B, suggesting that the decrease of BMP8B can lead to decreased glucose tolerance and insulin resistance in the body. Robinson and colleagues showed that while resting energy expenditure was similar in women with and without PCOS, postprandial thermogenesis was reduced in both obese and lean women with PCOS [52]. This decreased postprandial thermogenesis may predispose women with PCOS to weight gain and help to explain the

increased prevalence of obesity in women with PCOS. In our study, the serum BMP8b level of overweight or obese PCOS patients was significantly lower than that of normal weight patients, which may be related to the effect of BMP8b on adipogenesis. we showed that BMP8B down-regulates transcriptional regulators PPAR γ and C/EBP α , thereby impeding the differentiation of 3T3-L1 preadipocytes into fully mature adipocytes. BMP8B increased the phosphorylation levels of SMAD2/3, and TP0427736 HCl (SMAD2/3 inhibitor) significantly reduced the ability of BMP8B to inhibit adipocyte differentiation, suggesting that BMP8B repressed adipocyte differentiation through the SMAD2/3 pathway. Moreover, the knockdown of BMP I receptor ALK4 significantly reduced the inhibitory effect of BMP8B on adipogenesis, indicating that BMP8B triggers SMAD2/3 signaling to suppress adipogenesis via ALK4. In addition, BMP8B activated the NF- κ B signal, which has been demonstrated to impede PPAR γ expression. Collectively, our data demonstrated that BMP8B activates both SMAD2/3 and NF- κ B signals to inhibit adipocyte differentiation[53,54], leads to a buildup of fat cells that can lead to overweight or obesity. In addition, we found that triglyceride level in PCOS patients was significantly higher than that in normal patients, which was negatively correlated with serum BMP8B level and positively correlated with BMI and IR of patients. This suggests that BMP8B is involved in the regulation of lipid metabolism. When the lipid metabolism in the body is abnormal, the precursor of androgen synthesis, cholesterol, will produce a large amount of androgens under the action of 17 α -hydroxylase and 1720-lyase, while obese PCOS women have more serious endocrine hormone disorders and lipid metabolism abnormalities[55,56].

In summary, by studying the expression of brown adipokine BMP8B in the serum of PCOS patients and its relationship with PCOS, obesity, insulin resistance and triglyceride, this paper suggests that BMP8B can promote thermogenesis and weight loss in obesity. At the same time, BMP8B is involved in the regulation of body fat metabolism, can improve glucose intolerance and insulin resistance. In addition, studies have shown that stimulating BAT activity [57] or transplanting BAT into rodent models of PCOS can improve reproductive and metabolic function [58]. Therefore, we speculate that BAT may be a new target for PCOS treatment.

REFERENCES:

1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Boston. 1992;77–84.
2. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). J Hum Reprod (Oxford, England) 2004;19(1):41–47. doi: 10.1093/humrep/deh098.
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237–4245. doi: 10.1210/jc.2006-0178.
4. Bozdog G, Mumusoglu S, Zengin D, Karabulut E, Yildiz B. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. J Hum Reprod (Oxford, England) 2016;31(12):2841–2855. doi: 10.1093/humrep/dew218.
5. Dapas M, Lin F, Nadkarni G, Sisk R, Legro R, Urbanek M, et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering

- analysis. *J PLoS Med.* 2020;17(6):e1003132. doi: 10.1371/journal.pmed.1003132.
6. Legro RS, Arslanian SA, Ehrmann DA, et al. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2013; 98(12): 4565–4592,doi: 10.1210/jc.2013-2350, indexed in Pubmed: 24151290.
7. Jayasena CN, Franks S. The management of patients with polycystic ovary syndrome. *J Nat Rev Endocrinol.* 2014; 10(10): 624–636, doi:10.1038/nrendo.2014.102, indexed in Pubmed: 25022814.
8. Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med.* 2005; 352(12):1223–1236, doi: 10.1056/NEJMra041536, indexed in Pubmed: 15788499.
9. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab.* 2004; 89(6): 2745–2749, doi: 10.1210/jc.2003-032046, indexed in Pubmed: 15181052.
10. Symonds ME, Pope M, Budge H. The Ontogeny of Brown Adipose Tissue. *J Annu Rev Nutr.* 2015; 35:295–320. doi: 10.1146/annurev-nutr-071813-105330
11. Yang J, Zhang H, Parhat K, Xu H, Li M, Wang X, et al.. Molecular Imaging of Brown Adipose Tissue Mass. *Int J Mol Sci.* 2021; 22(17):9436. doi: 10.3390/ijms22179436
12. Villarroya F, Cereijo R, Villarroya J, Giralt M. Brown Adipose Tissue as a Secretory Organ. *J Nat Rev Endocrinol.* 2017;13(1):26–35. doi: 10.1038/nrendo.2016.136
13. Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, Idelson C, et al.. Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans. *J Cell Metab.* 2014; 19(2):302–9. doi: 10.1016/j.cmet.2013.12.017
14. Stanford KI, Middelbeek RJ, Townsend KL, An D, Nygaard EB, Hitchcox KM, et al.. Brown Adipose Tissue Regulates Glucose Homeostasis and Insulin Sensitivity. *J Clin Invest.* 2013;123(1):215–23. doi: 10.1172/jci62308
15. Svensson KJ, Long JZ, Jedrychowski MP, Cohen P, Lo JC, Serag S, et al.. A Secreted Slit2 Fragment Regulates Adipose Tissue Thermogenesis and Metabolic Function. *J Cell Metab.* 2016;23(3):454–66. doi: 10.1016/j.cmet.2016.01.008
16. Cristina Garcia-Beltran, Joan Villarroya, Cristina Plou, Aleix Gavalda-Navarro, Paula Casano, Rubén Cereijo, Francis de Zegher, Abel López-Bermejo, Lourdes Ibáñez, Francesc Villarroya. Bone Morphogenetic Protein-8B Levels at Birth and in the First Year of Life: Relation to Metabolic-Endocrine Variables and Brown Adipose Tissue Activity. *J Front Pediatr.* 2022; 24:10:869581. doi: 10.3389/fped.2022.869581.
17. MAHLI A, SEITZ T, BECKROGE T, et al. Bone morphogenetic protein-8B expression is induced in steatotic hepatocytes and promotes hepatic steatosis and inflammation in vitro. *J Cells.* 2019;15;8(5):457. doi: 10.3390/cells8050457.
18. Chinese Society of Health Management, Clinical Nutrition Branch of Chinese Nutrition Society, Medical Nutrition Industry Branch of the National Association of Health Industry and Enterprise Management, the Editorial Board of Chinese Journal of Health Management. Expert consensus on the procedure of body weight management among patients with overweight or obesity (2021) *Chin J Health Manage.* 2021; 15(4):317-322.
19. Helena J. Teede, Chau Thien Tay, Joop J.E. Laven, Anuja Dokras, Lisa J. Moran, Terhi T. Piltonen, Michael F. Costello, Jacky Boivin, Leanne M. Redman, Jacqueline A. Boyle, Robert J. Norman, Aya Mousa, and Anju E. Joham on behalf of the International PCOS Network. Recommendations from the 2023 international evidence-based guideline for the assessment

- and management of polycystic ovary syndrome. *J. European Journal of Endocrinology*, 2023, 189, 43–64. doi.org/10.1093/ejendo/lvad096
20. Xing XY, Yang WY, Yang ZJ: The diagnostic significance of homeostasis model assessment of insulin resistance in metabolic syndrome among subjects with different glucose tolerance. *Chin J Diabetes* 2004, 2:182-6.
21. Tai ES, Lim SC, Chew SK, Tan BY, Tan CE: Homeostasis model assessment in a population with mixed ethnicity: the 1992 Singapore National Health Survey. *J. Diabetes Res Clin Pract* 2000, 49:159-68.
22. Apridonidze T., Essah P.A., Iuorno M.J., Nestler J.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 2005;90:1929–1935. doi: 10.1210/jc.2004-1045.
23. Bil E., Dilbaz B., Cirik D.A., Ozelci R., Ozkaya E., Dilbaz S. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. *J. Obstet. Gynaecol. Res.* 2016;42:837–843. doi: 10.1111/jog.12985.
24. Daan N.M., Louwers Y.V., Koster M.P., Eijkemans M.J., de Rijke Y.B., Lentjes E.W., Fauser B.C., Laven J.S. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: Who is really at risk? *J. Fertil. Steril.* 2014;102:1444–1451.e3. doi: 10.1016/j.fertnstert.2014.08.001.
25. Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. *J Endocr. Rev.* 2012;33:981–1030. doi: 10.1210/er.2011-1034.
26. Nestler J.E., Jakubowicz D.J., de Vargas A.F., Brik C., Quintero N., Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. *J. Clin. Endocrinol. Metab.* 1998;83:2001–2005. doi: 10.1210/jcem.83.6.4886.
27. Cadagan D., Khan R., Amer S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. *J Reprod. Biol.* 2016;16:53–60. doi: 10.1016/j.repbio.2015.12.006.
28. Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. *J. Endocrinol.* 2007;192:585–594. doi: 10.1677/joe.1.07070.
29. Milutinović D.V., Nikolić M., Veličković N., Djordjevic A., Bursać B., Nestorov J., Teofilović A., Antić I.B., Macut J.B., Zidane A.S., et al. Enhanced Inflammation without Impairment of Insulin Signaling in the Visceral Adipose Tissue of 5 α -Dihydrotestosterone-Induced Animal Model of Polycystic Ovary Syndrome. *J Exp. Clin. Endocrinol. Diabetes.* 2017;125:522–529. doi: 10.1055/s-0043-104531.
30. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. *J. Clin. Investig.* 2011;121:2111–2117. doi: 10.1172/JCI57132.
31. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. *J Nat. Rev. Immunol.* 2011;11:85–97. doi: 10.1038/nri2921.
32. Song J., Deng T. The Adipocyte and Adaptive Immunity. *J Front. Immunol.* 2020;11:593058. doi: 10.3389/fimmu.2020.593058.
33. Cao H. Adipocytokines in obesity and metabolic disease. *J. Endocrinol.* 2014;220:T47–T59.

doi: 10.1530/JOE-13-0339.

34. Legro R.S., Kusanman A.R., Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. *Am. J. Med.* 2001;111:607–613. doi: 10.1016/S0002-9343(01)00948-2.
35. Yilmaz M., Biri A., Bukan N., Karakoç A., Sancak B., Törüner F., Paşaoğlu H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. *Gynecol. J. Endocrinol.* 2005;20:258–263. doi: 10.1080/09513590400027265.
36. Cannon B., Nedergaard J. Brown adipose tissue: Function and physiological significance. *J. Physiol. Rev.* 2004;84:277–359. doi: 10.1152/physrev.00015.2003.
37. Rasmussen A.T. The so-called hibernating gland. *J. Morphol.* 1923;38:147–205. doi: 10.1002/jmor.1050380106.
38. Ouellet V., Routhier-Labadie A., Bellemare W., Lakhal-Chaieb L., Turcotte E., Carpentier A.C., Richard D. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. *J. Clin. Endocrinol. Metab.* 2011;96:192–199. doi: 10.1210/jc.2010-0989.
39. Cypess A.M., Lehman S., Williams G., Tal I., Rodman D., Goldfine A.B., Kuo F.C., Palmer E.L., Tseng Y., Doria A., et al. Identification and Importance of Brown Adipose Tissue in Adult Humans. *N. Engl. J. Med.* 2009;360:1509–1517. doi: 10.1056/NEJMoa0810780.
40. Whittle A.J., Lopez M., Vidal-Puig A. Using brown adipose tissue to treat obesity—The central issue. *J. Trends Mol. Med.* 2011;17:405–411. doi: 10.1016/j.molmed.2011.04.001.
41. Yoneshiro T., Saito M. Activation and recruitment of brown adipose tissue as anti-obesity regimens in humans. *J. Ann. Med.* 2015;47:133–141. doi: 10.3109/07853890.2014.911595.
42. Avi Lerner, Drashti Kewada, Ayan Ahmed, Kate Hardy, Mark Christian, and Stephen Franks Androgen Reduces Mitochondrial Respiration in Mouse Brown Adipocytes: A Model for Disordered Energy Balance in Polycystic Ovary Syndrome. *Int J Mol Sci.* 2021 Jan; 22(1): 243. doi: 10.3390/ijms22010243
43. Whittle A.J., S C., L M., Slawik M., Hondares E., Vázquez M.J., et al. Bmp8b increases brown adipose tissue thermogenesis through both central and peripheral actions. *J. Cell.* 2012;149(4):871–885. doi: 10.1016/j.cell.2012.02.066.
44. Martins L., Seoane-Collazo P., Contreras C., Gonzalez-Garcia I., Martinez-Sanchez N., Gonzalez F., et al. A functional link between AMPK and orexin mediates the effect of BMP8B on energy balance. *J. Cell Reports.* 2016;16(8):2231–2242. doi: 10.1016/j.celrep.2016.07.045.
45. Pellegrinelli V., Peirce V.J., Howard L., Virtue S., Turei D., Senzacqua M., et al. Adipocyte-secreted BMP8b mediates adrenergic-induced remodeling of the neuro-vascular network in adipose tissue. *J. Nature Communications.* 2018;9(1):4974. doi: 10.1038/s41467-018-07453-x.
46. Rodriguez A.M., Monjo M., Roca P., Palou A. Opposite actions of testosterone and progesterone on UCP1 mRNA expression in cultured brown adipocytes. *J. Cell Mol. Life Sci.* 2002;59:1714–1723. doi: 10.1007/PL00012499.
47. Monjo M., Rodríguez A.M., Palou A., Roca P. Direct effects of testosterone, 17 beta-estradiol, and progesterone on adrenergic regulation in cultured brown adipocytes: Potential mechanism for gender-dependent thermogenesis. *J. Endocrinology.* 2003;144:4923–4930. doi: 10.1210/en.2003-0537.
48. Petersen K.F., Dufour S., Befroy D., Garcia R., Shulman G.I. Impaired mitochondrial activity

- in the insulin-resistant offspring of patients with type 2 diabetes. *J N. Engl. J. Med.* 2004;350:664–671. doi: 10.1056/NEJMoa031314.
49. Mogensen M., Sahlin K., Fernström M., Glintborg D., Vind B.F., Beck-Nielsen H., Højlund K. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. *J Diabetes.* 2007;56:1592–1599. doi: 10.2337/db06-0981.
50. Cheng Z., Guo S., Copps K., Dong X., Kolipara R., Rodgers J.T., Depinho R.A., Puigserver P., White M.F. Foxo1 integrates insulin signaling with mitochondrial function in the liver. *J Nat. Med.* 2009;15:1307–1311. doi: 10.1038/nm.2049.
51. YAN S, ZHOU X, WU C, et al. Adipocyte YTH N (6)-methyl adenosine RNA-binding protein 1 protects against obesity by promoting white adipose tissue beiging in male mice. *J Nat Commun.* 2023, 14 (1) : 1379. doi: 10.1038/s41467-023-37100-z.
52. Robinson S., Chan S.P., Spacey S., Anyaoku V., Johnston D.G., Franks S. Postprandial Thermogenesis Is Reduced in Polycystic-Ovary-Syndrome and Is Associated with Increased Insulin Resistance. *J Clin. Endocrinol.* 1992;36:537–543. doi: 10.1111/j.1365-2265.1992.tb02262.x.
53. Heldin C.H., Miyazono K., Ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. *Nature.* 1997;390:465–471. doi: 10.1038/37284.
54. Shenjie Zhong, Xueqing Du, Jing Gao, Guangdong Ji, Zhenhui Liu. BMP8B Activates Both SMAD2/3 and NF-κB Signals to Inhibit the Differentiation of 3T3-L1 Preadipocytes into Mature Adipocytes. *J Nutrients.* 2024; 16(1): 64 doi: 10.3390/nu16010064
55. Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community based study. *J Hum Reprod.* 2013;28(9) :2562-2569. doi: 10.1093/humrep/det262.
56. Zeng X, Xie Y, Liu Y, et al. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. *J Clin Chim Acta.* 2019;502:214-221. doi: 10.1016/j.cca.2019.11.003.
57. Rongcai Ye, Chunlong Yan, Huiqiao Zhou, Yuanyuan Huang, Meng Dong, Hanlin Zhang, Xiaoxiao Jiang, Shouli Yuan, Li Chen, Rui Jiang, Ziyu Cheng, Kexin Zheng, Qiaoli Zhang, and Wanzhu Jin. Brown Adipose Tissue Activation by Cold Treatment Ameliorates Polycystic Ovary Syndrome in Rat. *J Front Endocrinol (Lausanne).* 2021; 12: 744628. doi : 10.3389/fendo.2021.744628.
58. Xiaoxue Yuan, Tao Hu, Han Zhao, Yuanyuan Huang, Rongcai Ye, Jun Lin, Chuanhai Zhang, Hanlin Zhang, Gang Wei, Huiqiao Zhou, Meng Dong, Jun Zhao, Haibin Wang, Qingsong Liu, Hyuek Jong Lee, Wanzhu Jin, and Zi-Jiang Chen. Brown adipose tissue transplantation ameliorates polycystic ovary syndrome. *J Proc Natl Acad Sci USA.* 2016; 113(10): 2708–2713. doi: 10.1073/pnas.1523236113

